These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

705 related articles for article (PubMed ID: 22466482)

  • 21. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial.
    Zhao M; Zhang F; Chen Y; Dai H; Qu J; Dong C; Kang X; Liu Y; Yang L; Li Y; Zhou P; Pan CT; Zhang L; Liu P; Zhou H; Jiao X; Xiong Y; Tian R; Lu Y; Yu X; Li X
    JAMA Ophthalmol; 2015 Mar; 133(3):333-40. PubMed ID: 25555191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
    Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Hashizume K; Mizota A; Yuzawa M
    Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy.
    Kim YK; Ryoo NK; Woo SJ; Park KH
    Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2063-73. PubMed ID: 25616728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Photodynamic therapy in a patient with chronic central serous chorioretinopathy--a case report].
    Pociej W; Karska-Basta I; Kolár L; Oleksy P; Romanowska-Dixon B
    Klin Oczna; 2014; 116(1):28-31. PubMed ID: 25137918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy.
    Hayashida M; Miki A; Honda S; Nakamura M
    Photodiagnosis Photodyn Ther; 2020 Sep; 31():101955. PubMed ID: 32818640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial.
    Wu ZH; Lai RY; Yip YW; Chan WM; Lam DS; Lai TY
    Retina; 2011; 31(7):1378-86. PubMed ID: 21836413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy.
    Lim JI; Glassman AR; Aiello LP; Chakravarthy U; Flaxel CJ; Spaide RF;
    Ophthalmology; 2014 May; 121(5):1073-8. PubMed ID: 24439758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional retinal changes measured by microperimetry in standard-fluence vs low-fluence photodynamic therapy in chronic central serous chorioretinopathy.
    Reibaldi M; Boscia F; Avitabile T; Uva MG; Russo A; Zagari M; Occhipinti F; Russo V; Reibaldi A; Longo A
    Am J Ophthalmol; 2011 Jun; 151(6):953-960.e2. PubMed ID: 21457929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment.
    Arf S; Hocaoglu M; Sayman Muslubas I; Karacorlu M
    Int Ophthalmol; 2017 Jun; 37(3):483-489. PubMed ID: 27392913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
    Noh SR; Kang MS; Kim K; Kim ES; Yu SY
    Korean J Ophthalmol; 2019 Dec; 33(6):506-513. PubMed ID: 31833247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term results of low-fluence photodynamic therapy for chronic central serous chorioretinopathy.
    Leys E; Tuttle S; Rasquin F; Neu F; Postelmans L
    J Fr Ophtalmol; 2015 Oct; 38(8):709-16. PubMed ID: 26345542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy.
    Maruko I; Iida T; Sugano Y; Ojima A; Ogasawara M; Spaide RF
    Ophthalmology; 2010 Sep; 117(9):1792-9. PubMed ID: 20472289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy.
    Lim SH; Chang W; Sagong M
    Eye (Lond); 2013 Mar; 27(3):353-62. PubMed ID: 23449515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of photodynamic therapy on macular sensitivity in eyes with acute central serous chorioretinopathy.
    Hagen S; Ansari-Shahrezaei S; Smretschnig E; Glittenberg C; Krebs I; Graf A; Binder S
    Graefes Arch Clin Exp Ophthalmol; 2013 Apr; 251(4):1081-9. PubMed ID: 22926253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Choroidal Thickness Changes After Photodynamic Therapy and Recurrence of Chronic Central Serous Chorioretinopathy.
    Kim YK; Ryoo NK; Woo SJ; Park KH
    Am J Ophthalmol; 2015 Jul; 160(1):72-84.e1. PubMed ID: 25887629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COMPARISON OF HALVING THE IRRADIATION TIME OR THE VERTEPORFIN DOSE IN PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Shiode Y; Morizane Y; Kimura S; Hosokawa M; Kawata T; Doi S; Hosogi M; Fujiwara A; Shiraga F
    Retina; 2015 Dec; 35(12):2498-504. PubMed ID: 26035398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Photodynamic therapy for acute central serous chorioretinopathy: the safe effective lowest dose of verteporfin.
    Zhao MW; Zhou P; Xiao HX; Lv YS; Li CA; Liu GD; Li XX
    Retina; 2009 Sep; 29(8):1155-61. PubMed ID: 19629018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantification of metamorphopsia in chronic central serous chorioretinopathy after half-dose verteporfin photodynamic therapy.
    Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Mizota A; Yuzawa M
    Retina; 2014 May; 34(5):964-70. PubMed ID: 24406387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Photodynamic therapy for chronic central serous chorioretinopathy and diffuse retinal epitheliopathy].
    Cornut PL; Quaranta-El Maftouhi M; Mauget-Faÿsse M
    J Fr Ophtalmol; 2012 Feb; 35(2):82-7. PubMed ID: 21889817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
    Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ
    Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.